Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients


22 Nov 2020


e-Poster Display Session


Tumour Site

Breast Cancer


Sumadi Lukman Anwar


Annals of Oncology (2020) 31 (suppl_6): S1257-S1269. 10.1016/annonc/annonc353


S.L. Anwar1, W.S. Avanti2, R. Cahyono1, L. Choridah2, W.A. Harahap3, T. Aryandono4

Author affiliations

  • 1 Surgery, Surgical Oncology, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID
  • 2 Radiology, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID
  • 3 Surgery, Surgical Oncology, Faculty of Medicine, Andalas University, 25127 - Padang/ID
  • 4 Surgery, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 60P


The bone is the most common site of distant metastasis from breast cancer that predisposes the patients for skeletal-related events (SREs) and often causes severe morbidity and poor quality of life. Identification of predilections and risk factors associated with bone metastasis and SREs is important in planning (neo)adjuvant treatment and surveillance systems particularly in a population of patients diagnosed in late stages such as in Indonesia and other developing countries.


Clinicopathological variables of breast cancer with intermediate to the high-high risk of recurrence were collected from a dataset in the Dr Sardjito Hospital, Indonesia. Risk factors affecting bone metastasis and SRE were then analyzed.


Of 1081 non-metastatic breast cancer patients diagnosed from 2013 through 2018, 129 patients (11.9%) developed bone metastasis during a median follow up of 4.4 years. SREs occurred in 89 (68.5%) patients. In multivariable analysis, positive axillary lymph nodes (OR 2.189, p=0.002), early menopause (OR 2.020, p=0.030), luminal subtype (OR 1.811, p=0.003), advanced stage (OR 1.869, p=0.004), and having multiple metabolic comorbidities (OR 1.992, p=0.004) were significantly associated with risk of skeletal metastasis. Only positive lymph nodes, luminal subtype, and advanced stages were associated with higher SREs. Of 102 (82.2%) and 52 (40.3%) patients received bone-modifying agents and external radiotherapy, respectively.


The rates of bone metastasis and SREs are relatively high in breast cancer patients diagnosed in advanced stages. Our study suggests the importance of considering patients with high-risk of SREs and the need of treatment advancement to further prevent SREs in the care of breast cancer with bone metastasis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sumadi Lukman Anwar.


Universitas Gadjah Mada.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.